Shares of KALA BIO KALA have nosedived 88.3% in a month after the company announced the failure of a mid-stage study evaluating its only clinical pipeline candidate, KPI-012, for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback